Introduction
============

Lung cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer-related death. Non-small-cell lung cancer (NSCLC) accounts for 80%--85% all lung cancer cases.[@b1-ott-8-3595] The majority of patients with NSCLC present with advanced disease.[@b2-ott-8-3595] Thus, despite improved forms of treatment (chemotherapy, radiotherapy, and surgery), the 5-year survival rate is still \<15%.[@b3-ott-8-3595] Tumor node metastasis stage, patient age, performance status, and weight loss have been identified as independent prognostic factors in NSCLC.[@b4-ott-8-3595] However, because the predictive power of these factors is unreliable,[@b5-ott-8-3595],[@b6-ott-8-3595] more broadly useful prognostic biomarkers are needed.

In the treatment of several kinds of cancer, including lung cancer, potential therapeutic targets such as epidermal growth factor receptor (EGFR),[@b7-ott-8-3595] Kirsten rat sarcoma viral oncogene,[@b8-ott-8-3595] and human EGFR-2,[@b9-ott-8-3595] have been the focus of recent attention. Yet, the development of drugs aimed at these targets has been hampered by drug resistance and a high mutation rate of the relevant genes.

The surface receptor programmed cell death 1 (PD-1) is a 288-amino acid cell surface protein and a member of the B7-CD28 superfamily.[@b10-ott-8-3595] PD-1 is expressed on the surface of activated T and B cells and regulates their activation and proliferation.[@b11-ott-8-3595] PD-ligand 1 (PD-L1) binds to the PD-1 receptor, leading to, among other responses, the negative regulation of immune activity. PD-L1 is also thought to be involved in the ability of cancer cells to evade host immune surveillance.[@b12-ott-8-3595] For example, PD-L1 expressed on tumor cells was shown to promote apoptosis of antigen-specific and tumor-reactive T-cells, resulting in enhanced tumor cell growth. PD-L1 expression has been evaluated in a number of human cancers, including NSCLC, melanoma, esophageal adenocarcinoma, kidney tumors, and breast, bladder, ovarian, pancreatic, and esophageal cancers.[@b13-ott-8-3595]--[@b17-ott-8-3595] However, studies on the prognostic value of PD-L1 expression in patients with NSCLC have yielded inconsistent results and have been limited by their low statistical power.[@b18-ott-8-3595]--[@b28-ott-8-3595] To address these issues, we conducted a meta-analysis to determine the prognostic value of PD-L1 expression in patients with NSCLC.

Materials and methods
=====================

We performed this meta-analysis according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses.[@b29-ott-8-3595]

Literature search
-----------------

A comprehensive literature search was performed using the electronic databases PubMed, Embase, China National Knowledge Infrastructure, and Wanfang. The last search was performed on June 10, 2015. The search terms used were as follows: "Programmed cell death-ligand 1", "PD-L1", "B7-H1", "lung cancer", "survival", and "prognosis". All references cited in relevant articles were also checked to identify additional published work. No restrictions were applied during database searching, which was performed independently by two investigators.

Inclusion and exclusion criteria
--------------------------------

Studies eligible for inclusion in this meta-analysis had to meet the following criteria: 1) the cancer was histologically confirmed as NSCLC; 2) PD-L1 expression was measured in lung cancer tissue using immunohistochemistry (IHC); 3) the association between PD-L1 expression and NSCLC prognosis was investigated; 4) sufficient data were available to estimate overall survival (OS) or associations between PD-L1 expression; and 5) PD-L1 expression was scored as "high (positive)" or "low (negative)". To avoid duplication of the data, only the most complete and recent of two related studies were included. Exclusion criteria were: 1) studies reported in reviews or letters, ongoing studies, and conference papers; 2) nonclinical studies and studies of other types of cancer; and 3) studies with insufficient survival data.

Data extraction
---------------

Two investigators (AZ and YX) extracted the following required data independently from all eligible studies: the first author's name, year of publication, country, cancer type, cancer stage, test method, cutoff value for positive PD-L1 expression, primary antibody, sample size, hazard ratio (HR) estimation method, and treatment. Discrepancies in data collection were resolved by group discussion. Questions were resolved, and details from a particular study were obtained by contacting the study authors via email.

Statistical analysis
--------------------

All statistical analyses were performed using Stata software (v11.0; StataCorp LP, College Station, TX, USA). HRs with 95% confidence intervals (CIs) were used to assess the effect of high PD-L1 expression on the survival of patients with NSCLC. If these data were provided indirectly, the HRs and 95% CIs were calculated according to Tierney's methods.[@b30-ott-8-3595] Subgroup analyses were performed with respect to the geographic region of the patients, cancer type, HR estimation methods, primary antibody (source and type), and treatment method. Heterogeneity among studies was tested using the Q and *I*^2^ statistics. For *P*\>0.10, the Mantel--Haenszel fixed-effects model was used; otherwise, DerSimonian and Laird's random-effects model was used.[@b31-ott-8-3595],[@b32-ott-8-3595] A sensitivity analysis was performed by a leave-one-out procedure.[@b33-ott-8-3595] Publication bias was evaluated using a funnel plot and objective Begg's or Egger's tests.[@b34-ott-8-3595],[@b35-ott-8-3595] Unless otherwise stated, *P*\<0.05 was considered to be statistically significant.

Results
=======

Search results
--------------

After searching the aforementioned electronic databases, 125 references were obtained. Of these, 33 references were excluded because of duplication, and another 35 (26 reviews, one letter, two ongoing studies, and six conference papers) were excluded after their titles and abstracts were read. After the full-text of the remaining articles was read, 22 nonclinical studies, five studies referring to other types of cancer, and 19 studies with insufficient survival data were further excluded. Thus, ultimately, eleven articles reporting on 12 studies were included in our meta-analysis and were subjected to further statistical evaluation ([Figure 1](#f1-ott-8-3595){ref-type="fig"}).

Study characteristics
---------------------

[Table 1](#t1-ott-8-3595){ref-type="table"} summarizes the characteristics of the included studies. The year of publication ranged from 2010 to 2015. The 12 studies reported by the eleven articles included a total of 1,653 participants. Eight of the studies were performed in the People's Republic of China and the other four in Japan, Greece, the USA, and Italy (one each). The sample size of the included studies ranged from 47 to 340. Five studies consisted of patients with stages I--III NSCLC, three studies included patients with stages IIIB--IV disease, and another three studies comprised patients with stages I--IV disease. With respect to the histological type of NSCLC, three studies evaluated patients with adenocarcinoma, and the others focused on NSCLC including adenocarcinoma, squamous cell cancer, and large cell cancer. All studies used IHC to evaluate PD-L1 expression in patients with NSCLC. In the four articles that did not report HRs and 95% CIs directly, Kaplan--Meier curves were used to calculate these statistics.

PD-L1 expression and OS
-----------------------

The pooled results of the 12 trials comprising 1,653 patients did not show a statistically significant relationship between PD-L1 expression and OS (HR =1.21, 95% CI: 0.85--1.71, *P*=0.29). However, there was significant between-study heterogeneity (*I*^2^=82%, *P*\<0.001) ([Figure 2](#f2-ott-8-3595){ref-type="fig"}).

Subgroup analysis between PD-L1 expression and OS
-------------------------------------------------

Subgroup analysis showed that PD-L1 expression was significantly associated with poor prognosis in Chinese patients (HR =1.55, 95% CI: 1.04--2.29, *P*=0.03). In the remaining subgroups, a statistical relationship between PD-L1 expression and NSCLC prognosis could not be determined. The results of the subgroup analyses are presented in [Table 2](#t2-ott-8-3595){ref-type="table"}.

Sensitivity analyses
--------------------

Sensitivity analysis was conducted by sequentially omitting each trial one at a time. The results showed that no single trial remarkably altered the pooled results for OS, suggesting they were robust and reliable ([Figure 3](#f3-ott-8-3595){ref-type="fig"}).

Publication bias
----------------

According to Begg's test (*P*=0.20) and Egger's test (*P*=0.53), there was no significant publication bias for any of the outcomes. The shape of the funnel plots did not indicate any obvious asymmetry ([Figure 4](#f4-ott-8-3595){ref-type="fig"}).

Discussion
==========

The aim of this meta-analysis was to explore the association between PD-L1 expression and the prognosis of patients with NSCLC. It was based on eleven eligible articles reporting on 12 studies with a total of 1,653 patients. The pooled data indicated no statistically significant difference between PD-L1 expression and prognosis in NSCLC. However, a subgroup analysis showed an association between PD-L1 expression and poor prognosis in studies conducted in the People's Republic of China. The prognostic role of PD-L1 expression in NSCLC has been evaluated extensively. Chen et al[@b20-ott-8-3595] and Mao et al[@b26-ott-8-3595] reported increased PD-L1 expression in NSCLC patients with poorly differentiated tumors and lymph node metastasis. High PD-L1 levels were shown to be associated with a significantly shorter OS. The relationship between PD-L1 expression and poor prognosis in NSCLC was confirmed in three other studies,[@b18-ott-8-3595],[@b19-ott-8-3595],[@b21-ott-8-3595] whereas in another two studies,[@b23-ott-8-3595],[@b27-ott-8-3595] patients with NSCLC and higher PD-L1 expression had a better cumulated survival rate. In the remaining included studies, a significant correlation between PD-L1 expression and OS could not be established.[@b22-ott-8-3595],[@b24-ott-8-3595],[@b25-ott-8-3595],[@b28-ott-8-3595] However, the differences in the definition of PD-L1-positivity/negativity and therapeutic regimen and the small sample sizes may have accounted for the contradictory results.

A potential association between PD-L1 expression and the prognosis of patients with NSCLC was assessed in previous meta-analyses.[@b36-ott-8-3595]--[@b39-ott-8-3595] In three meta-analyses, it was found that NSCLC patients positive for PD-L1 expression had a poor OS.[@b36-ott-8-3595],[@b37-ott-8-3595],[@b39-ott-8-3595] In another meta-analysis, PD-L1 was not a prognostic predictor for NSCLC.[@b38-ott-8-3595] However, the combined sample size of the three analyses was relatively small such that the results may not have been representative. Our meta-analysis enrolled nearly twice as many studies that consisted of nearly twice as many patients. The robustness of our results was established in subgroup and sensitivity analyses.

According to the subgroup analysis, high PD-L1 expression was a poor prognostic factor in Chinese but not in non-Chinese patients with NSCLC, which suggests that the association is dependent on race. In some studies, Chinese patients were pretreated with chemotherapy or surgery. However, some non-Chinese patients were also pretreated with these agents, and there have been no studies showing that these therapeutic agents affect the levels of PD-L1. The high PD-L1 expression in Chinese patients might be explained by the following: 1) three Chinese studies only included lung adenocarcinoma, and expression of PD-L1 increased in patients with these adenocarcinomas; and 2) the incidence of EGFR mutations was higher in East Asian patients than in Caucasian patients, because activation of the EGFR pathway induced PD-L1 expression. Thus, high PD-L1 expression may have existed.

There was also significant heterogeneity across the included studies. However, subgroup analyses of geographic region, cancer type, the methods used to estimate the HR, and the primary antibody used (source and type) failed to identify its source. Therefore, it is likely that the heterogeneity derived from differences in the baseline characteristics of the patients, the IHC methods used, the definition of positive/high PD-L1 expression, treatment, or the duration of follow-up. However, due to a lack of clinical information on these aspects, their contribution to the study heterogeneity could not be determined.

Regardless of these limitations, the results of the present study suggest that, in clinical trials, when anti-PD-L1 antibodies are used for cancer immunotherapy, patients with NSCLC should be carefully selected. Furthermore, PD-L1 is not a predictive biomarker for prognoses. Future studies involving the detection of PD-L1 expression in clinical applications should include larger sample sizes. Nonetheless, the present meta-analysis will provide useful guidelines for future studies. In the current meta-analysis, no publication bias was detected, and a sensitivity analysis showed that the conclusions were unchanged when any one study was omitted. Nonetheless, our meta-analysis had several limitations. First, both the pooled sample size and the sample size of each included study were relatively small. Despite pooling data from more than 1,500 patients with NSCLC, our study still lacked statistical power. Second, several HRs were extracted from Kaplan--Meier curves, which might have biased our results. Third, although all of the included studies detected PD-L1 expression using IHC, many different antibodies were used. The H-score was used to detect PD-L1 levels in eight studies, while the other studies used automated quantitative analysis. The cutoff values for positive PD-L1 expression also varied between studies. New studies using the same cutoff values are therefore needed for further confirmation. Fourth, despite several subgroup analyses, we were unable to identify the source of the between-study heterogeneity. Finally, some clinical parameters, such as sex, smoking status, histology, tumor stage, the presence or absence of lymph node metastasis, and tumor cell differentiation, may have had an effect on the prognosis of NSCLC patients. These were unavoidable limitations of the included studies; therefore, we could not adjust these confounding factors using statistical methods. In summary, our meta-analysis showed no statistically significant relationship between PD-L1 expression and the prognosis of patients with NSCLC. Additional, high-quality studies with larger sample sizes are needed to determine the prognostic value of PD-L1 expression in NSCLC.
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![Forest plot showing HR from random-effects model for the association between PD-L1 expression and OS.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; OS, overall survival.](ott-8-3595Fig2){#f2-ott-8-3595}
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![Funnel graph for assessment of potential publication bias in studies.\
**Abbreviations:** SE, standard error; HR, hazard ratio.](ott-8-3595Fig4){#f4-ott-8-3595}

###### 

Clinical characteristics of qualified records in meta-analysis

  Author                                                                        Year   Country                      Type    Stage      Cutoff          Antibody   Sample size   HR estimation methods               
  ----------------------------------------------------------------------------- ------ ---------------------------- ------- ---------- --------------- ---------- ------------- ----------------------- ----- ----- -----------------
  Mu et al[@b18-ott-8-3595]                                                     2011   People's Republic of China   NSCLC   I--III     Media H-score   NR         MAB           NR                      58    51    Survival curves
  Ma et al[@b19-ott-8-3595]                                                     2011   People's Republic of China   NSCLC   I--IV      H-score \>3     Rabbit     MAB           NR                      23    24    Survival curves
  Chen et al[@b20-ott-8-3595]                                                   2012   People's Republic of China   NSCLC   I--III     H-score \>3     Rabbit     PAB           NR                      69    51    HR and 95% CI
  Zhang et al[@b21-ott-8-3595]                                                  2014   People's Republic of China   ADC     I--III     H-score ≥80     Rabbit     PAB           SAB2900365              70    73    HR and 95% CI
  Yang et al[@b22-ott-8-3595]                                                   2014   People's Republic of China   ADC     I--IV      Percentage 5%   Rabbit     PAB           17952-1-AP              65    98    Survival curves
  Velcheti et al[@b23-ott-8-3595],[\*](#tfn2-ott-8-3595){ref-type="table-fn"}   2014   Greek                        NSCLC   I--IV      AQUA scores     Mouse      MAB           Clone 5H1               75    228   HR and 95% CI
  Velcheti et al[@b23-ott-8-3595],[\#](#tfn3-ott-8-3595){ref-type="table-fn"}   2014   USA                          NSCLC   I--IV      AQUA scores     Mouse      MAB           Clone 5H1               56    99    HR and 95% CI
  D'Incecco et al[@b24-ott-8-3595]                                              2014   Italy                        NSCLC   IIIB--IV   H-score \>3     NR         NR            ab58810                 49    46    Survival curves
  Azuma et al[@b25-ott-8-3595]                                                  2014   Japan                        NSCLC   I--III     H-score ≥30     Rabbit     PAB           NR                      82    82    HR and 95% CI
  Mao et al[@b26-ott-8-3595]                                                    2014   People's Republic of China   ADC     I--III     H-score \>3     Mouse      MAB           Clone 2H11              93    35    HR and 95% CI
  Lin et al[@b27-ott-8-3595]                                                    2015   People's Republic of China   NSCLC   IIIB--IV   Media H-score   NR         NR            ab58810                 30    26    HR and 95% CI
  Tang et al[@b28-ott-8-3595]                                                   2015   People's Republic of China   NSCLC   IIIB--IV   H-score ≥5      Rabbit     MAB           NR                      112   58    HR and 95% CI

**Notes:** H-score = SI (staining intensity) × PP (percentage of positive cells). SI was determined as 0, negative; 1, weak; 2, moderate; and 3, strong. PP was defined as 0, negative; 1--100, 1%--100% positive cells.

Greek cohort;

Yale cohort.

**Abbreviations:** NSCLC, non-small-cell lung cancer; ADC, adenocarcinoma; HR, hazard ratio; CI, confidence interval; AQUA, automated quantitative analysis; MAB, monoclonal antibody; PAB, polyclonal antibody; NR, not reported.

###### 

Subgroup analysis for the association between PD-L1 expression and OS

  Subgroup                                     No of study   No of patients   HR         95% CI           *P*-value   Heterogeneity   
  -------------------------------------------- ------------- ---------------- ---------- ---------------- ----------- --------------- ----------
  Overall                                      12            1,653            1.21       0.85--1.71       0.29        \<0.001         82
  Geographic region                                                                                                                   
   People's Republic of China                  **8**         **936**          **1.55**   **1.04--2.29**   **0.03**    **0.001**       **72.5**
   Other than the People's Republic of China   4             717              0.82       0.52--1.31       0.41        0.003           79.0
  Histological type (ADC %)                                                                                                           
   ≥50                                         9             1,170            1.11       0.77--1.62       0.57        \<0.001         78.0
   \<50                                        3             569              1.52       0.58--4.03       0.68        \<0.001         91.6
  HR estimated                                                                                                                        
   HR 95% CI                                   8             1,239            1.19       0.72--1.98       0.5         \<0.001         86.0
   Kaplan--Meier curve                         4             414              1.24       0.76--2.01       0.39        0.010           72.5
  Antibody source                                                                                                                     
   Mouse                                       3             586              0.88       0.45--1.74       0.30        0.003           83.1
  Rabbit                                       **6**         **807**          **1.78**   **1.39--2.27**   **0.03**    **0.222**       **28.4**
   NR                                          3             260              0.76       0.28--2.06       0.68        \<0.001         88.8
  Antibody type                                                                                                                       
   Monoclonal antibody                         6             912              1.24       0.80--1.91       0.23        \<0.001         81.5
  Polyclonal antibody                          **4**         **590**          **1.97**   **1.34--2.89**   **0.001**   **0.187**       **37.6**
   NR                                          2             151              1.15       0.43--3.10       0.78        0.013           83.7

**Notes:** Bold values indicate PD-L1 expression was significantly associated with poor prognosis in Chinese patients.

**Abbreviations:** PD-L1, programmed cell death-ligand 1; ADC, adenocarcinomas; HR, hazard ratio; CI, confidence interval; OS, overall survival; NR, not reported.
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